CABA - Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
2024-01-31 02:53:09 ET
Summary
- Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024.
- Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024.
- Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024.
- Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024.
Cabaletta Bio ( CABA ) f ast making headway with its lead asset CABA-201 for the treatment of patients with autoimmune disorders. This is a CD-19 CAR-T therapy being used for the treatment of patients with lupus nephritis [SLE of the kidney] and non-renal SLE as well. What makes this company unique would be its approach of attaching a 4-1BB co-stimulatory domain to the drug to enhance efficacy. The main form of the technology is known as Chimeric Antigen Receptor T cells for Autoimmunity [CARTA]. The goal is to go after SLE first, however, other autoimmune indications being explored are: Myositis, systemic sclerosis, and generalized myasthenia gravis, plus many more. Matter of fact, Cabaletta is already in the process of conducting four phase 1/2 studies using CABA-201 to treat patients with SLE, myositis, systemic sclerosis, and generalized myasthenia gravis [gMG]....
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward